Neurogene (NASDAQ:NGNE) Issues Earnings Results, Misses Estimates By $0.11 EPS

Neurogene (NASDAQ:NGNE) issued its quarterly earnings data on Tuesday. The company reported ($1.53) EPS for the quarter, missing analysts’ consensus estimates of ($1.42) by ($0.11), FiscalAI reports.

Neurogene Stock Up 3.3%

Shares of Neurogene stock opened at $36.98 on Thursday. Neurogene has a 12-month low of $15.93 and a 12-month high of $43.66. The firm has a market capitalization of $584.28 million, a PE ratio of -7.35 and a beta of 1.70. The stock’s fifty day moving average is $33.75 and its 200-day moving average is $26.71.

Wall Street Analyst Weigh In

Several equities analysts have recently issued reports on the stock. UBS Group set a $70.00 price target on shares of Neurogene in a report on Wednesday, June 3rd. HC Wainwright dropped their price target on shares of Neurogene from $70.00 to $65.00 and set a “buy” rating on the stock in a research note on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Neurogene in a research report on Friday, July 17th. Guggenheim raised their target price on Neurogene from $69.00 to $81.00 and gave the company a “buy” rating in a research note on Wednesday. Finally, Rodman & Renshaw assumed coverage on Neurogene in a report on Wednesday, June 3rd. They set a “buy” rating and a $70.00 target price on the stock. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $83.67.

Insiders Place Their Bets

In other Neurogene news, CFO Christine Mikail Cvijic sold 4,200 shares of the business’s stock in a transaction dated Tuesday, July 7th. The stock was sold at an average price of $36.13, for a total transaction of $151,746.00. Following the sale, the chief financial officer owned 84,040 shares in the company, valued at approximately $3,036,365.20. The trade was a 4.76% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last 90 days, insiders sold 9,600 shares of company stock valued at $339,932. Company insiders own 11.68% of the company’s stock.

Institutional Investors Weigh In On Neurogene

A number of large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its stake in Neurogene by 17.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 6,983 shares of the company’s stock worth $82,000 after purchasing an additional 1,059 shares during the period. Bank of America Corp DE lifted its holdings in shares of Neurogene by 81.6% in the second quarter. Bank of America Corp DE now owns 95,401 shares of the company’s stock valued at $1,426,000 after purchasing an additional 42,880 shares in the last quarter. BNP Paribas Financial Markets boosted its position in shares of Neurogene by 89.8% in the third quarter. BNP Paribas Financial Markets now owns 2,067 shares of the company’s stock worth $36,000 after buying an additional 978 shares during the period. Bridgeway Capital Management LLC acquired a new stake in shares of Neurogene in the third quarter worth $187,000. Finally, Balyasny Asset Management L.P. purchased a new position in shares of Neurogene during the third quarter valued at $12,114,000. Institutional investors and hedge funds own 52.37% of the company’s stock.

Neurogene Company Profile

Neurogene, Inc is a clinical‐stage biotechnology company specializing in the development of gene therapies for rare neurological diseases. The company’s lead platform employs adeno‐associated virus (AAV) vectors designed to deliver functional copies of disease-causing genes directly to the central nervous system. Neurogene’s pipeline focuses on inherited lysosomal storage disorders, including investigational programs for GM1 and GM2 gangliosidoses, with additional preclinical efforts targeting other monogenic neurodegenerative conditions.

Neurogene’s proprietary AAV9‐based delivery system has been engineered to cross the blood-brain barrier, aiming to provide durable gene expression in affected tissues.